<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874572</url>
  </required_header>
  <id_info>
    <org_study_id>CVB2018-2</org_study_id>
    <secondary_id>2018-003856-19</secondary_id>
    <nct_id>NCT03874572</nct_id>
  </id_info>
  <brief_title>Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth</brief_title>
  <acronym>MESRIX-SAFE</acronym>
  <official_title>A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia in Previous Oropharynx Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study investigates the feasibility and safety of allogeneic mesenchymal
      stem/stromal cells in previous oropharynx cancer patients with radiation-induced
      hyposalivation and xerostomia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyposalivation and xerostomia are the most common long-term side effects to radiotherapy of
      head and neck cancers.

      A randomized clinical trial indicates that autologeous mesenchymal stem/stromal cells can
      restore function of the submandibular glands.

      Patients with previous oropharynx cancer and radiation-induced hyposalivation and xerostomia
      will be treated with culture expanded adipose tissue derived mesenchymal stem/stromal cells
      from healthy donors.

      The patients will be followed for 4 months for safety and efficacy registration

      10 Healthy controls will be included for sialometry
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Actual">June 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of patients with serious adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>Registration of number of patients with serious adverse events in a 4 months follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response to treatment with allogeneic stem cells</measure>
    <time_frame>4 months</time_frame>
    <description>Registration of development of tissue antibodies towards donor cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Salivary gland function flow rate</measure>
    <time_frame>4 months</time_frame>
    <description>Change in unstimulated Whole saliva flow rate (Sialometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in quality of life</measure>
    <time_frame>4 months</time_frame>
    <description>Change in quality of life evaluted by QLQ-H&amp;N-35 and XQ questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Salivary gland function</measure>
    <time_frame>4 months</time_frame>
    <description>Assessed by salivary gland 99mTc scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Function of stimulated Whole saliva</measure>
    <time_frame>4 months</time_frame>
    <description>LC-MSMS analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Xerostomia Due to Radiotherapy</condition>
  <condition>Hyposalivation</condition>
  <condition>Xerostomia</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Salivary Gland Diseases</condition>
  <condition>Dry Mouth</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <condition>Mesenchymal Stromal Cells</condition>
  <condition>Stem Cells</condition>
  <arm_group>
    <arm_group_label>Allogeneic mesenchymal stem/stromal cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with intra-glandular Injections of allogeneic adipose derived stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic adipose derived stem/stromal cells</intervention_name>
    <description>Culture expanded allogeneic adipose derived stem/stromal cells</description>
    <arm_group_label>Allogeneic mesenchymal stem/stromal cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18-75 years

          2. Previous radiotherapy +/- chemotherapy for OPSCC stage I- II (UICC-8, 2017)

          3. 2 years' follow-up without recurrence

          4. Clinically reduced salivation and hyposalivation, evaluated by a screening

          5. Unstimulated salivary flow rate between 0.2mL/min and 0.05mL/min

          6. Grade 2-3 xerostomia (CTCAEv5.0)

          7. WHO Performance status (PS) 0-1

          8. Informed consent

        Exclusion Criteria:

          1. Any cancer in the previous 4 years (not including OPSCC and basocellular carcinomas)

          2. Xerogenic medications

          3. Penicillin or Streptomycin allergy

          4. Any other diseases of the salivary glands, e.g. Sj√∂gren's syndrome or sialolithiasis

          5. Previous parotid or submandibular gland surgery

          6. Previous treatment with any type of stem cells

          7. Breastfeeding, Pregnancy or planned pregnancy within the next 2 years

          8. Smoking within the previous 6 months.

          9. Alcohol abuse (consumption must not exceed 7 units/week for women and 14 units/week
             for men (Danish National board health alcohol guidelines3)

         10. Any other disease/condition judged by the investigator to be grounds for exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Lynggaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Otolaryngology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Charlotte Lynggaard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Xerostomia Due to Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
    <mesh_term>Salivary Gland Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study Protocol will be submitted with the data of the study</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

